These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 37857226)

  • 1. The prevalence of relevant drug-drug interactions and associated clinical outcomes in patients with cancer-associated thrombosis on concurrent anticoagulation and anticancer or supportive care therapies.
    Wang TF; Hill M; Mallick R; Chaudry H; Unachukwu U; Delluc A; Carrier M
    Thromb Res; 2023 Nov; 231():128-134. PubMed ID: 37857226
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anticoagulation for the long-term treatment of venous thromboembolism in people with cancer.
    Kahale LA; Hakoum MB; Tsolakian IG; Matar CF; Terrenato I; Sperati F; Barba M; Yosuico VE; Schünemann H; Akl EA
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD006650. PubMed ID: 29920657
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Complexity and clinical significance of drug-drug interactions (DDIs) in oncology: challenging issues in the care of patients regarding cancer-associated thrombosis (CAT).
    Tsoukalas N; Brito-Dellan N; Font C; Butler T; Rojas-Hernandez CM; Butler T; Escalante C;
    Support Care Cancer; 2022 Oct; 30(10):8559-8573. PubMed ID: 35932318
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Consensus on prevention and treatment of cancer-associated thrombosis (CAT) in controversial clinical situations with low levels of evidence.
    Jiménez-Fonseca P; Gallardo E; Arranz Arija F; Blanco JM; Callejo A; Lavin DC; Costa Rivas M; Mosquera J; Rodrigo A; Sánchez Morillas R; Vares Gonzaléz M; Muñoz A; Carmona-Bayonas A
    Eur J Intern Med; 2022 Jun; 100():33-45. PubMed ID: 35227541
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment Patterns and Clinical Outcomes in Korean Cancer Patients With Venous Thromboembolism: A Retrospective Cohort Study.
    Bang SM; Kang JH; Hong MH; Ahn JS; Oh SY; Baek JH; Choi YJ; Shin SH; Kim YJ; Gil HY; Park HE; Lee J; Park EL
    Clin Appl Thromb Hemost; 2021; 27():1076029620979575. PubMed ID: 33471574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparative Effectiveness of Anticoagulants in Patients With Cancer-Associated Thrombosis.
    Riaz IB; Fuentes H; Deng Y; Naqvi SAA; Yao X; Sangaralingham LR; Houghton DE; Padrnos LJ; Shamoun FE; Wysokinski WE; McBane RD
    JAMA Netw Open; 2023 Jul; 6(7):e2325283. PubMed ID: 37486628
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A single center retrospective cohort study comparing low-molecular-weight heparins to direct oral anticoagulants for the treatment of venous thromboembolism in patients with cancer - A real world experience.
    Phelps MK; Wiczer TE; Erdeljac HP; Van Deusen KR; Porter K; Philips G; Wang TF
    J Oncol Pharm Pract; 2019 Jun; 25(4):793-800. PubMed ID: 29460705
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Trends in Anticoagulant Utilization and Clinical Outcomes for Cancer-Associated Thrombosis: A Multicenter Cohort Study in Thailand's Upper-Middle-Income Country Setting.
    Kengkla K; Nathisuwan S; Sripakdee W; Saelue P; Sengnoo K; Sookprasert A; Subongkot S
    JCO Glob Oncol; 2024 Feb; 10():e2300353. PubMed ID: 38422463
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Direct oral anticoagulants in patients with venous thromboembolism and hematological malignancies.
    Robinson R; Spectre G; Lishner M; Sharabi O; Robinson E; Hamburger Avnery O; Gafter-Gvili A; Raanani P; Leader A
    J Thromb Thrombolysis; 2023 May; 55(4):729-736. PubMed ID: 36943661
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparative effectiveness and safety of direct oral anticoagulants (DOACs) versus conventional anticoagulation for the treatment of cancer-related venous thromboembolism: A retrospective analysis.
    Ross JA; Miller MM; Rojas Hernandez CM
    Thromb Res; 2017 Feb; 150():86-89. PubMed ID: 28064037
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison Between Non-vitamin K Antagonist Oral Anticoagulants and Low-Molecular-Weight Heparin in Asian Individuals With Cancer-Associated Venous Thromboembolism.
    Chen DY; Tseng CN; Hsieh MJ; Lan WC; Chuang CK; Pang ST; Chen SW; Chen TH; Chang SH; Hsieh IC; Chu PH; Wen MS; Chen JS; Chang JW; See LC; Huang WK
    JAMA Netw Open; 2021 Feb; 4(2):e2036304. PubMed ID: 33533929
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Net clinical benefit of DOACs vs. usual anticoagulation treatment in venous thromboembolism and active cancer: systematic review and meta-analysis.
    Michalopoulou H; Polyzos D; Thomopoulos C; Makavos G; Papamikroulis GA; Nikova A; Zakynthinos GΕ; Vavouranakis M; Siasos G; Vavouranakis E
    J Thromb Thrombolysis; 2023 Jan; 55(1):92-101. PubMed ID: 36307630
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug-drug interactions: Implications for anticoagulation, with focus in patients with cancer.
    Wang TF
    Thromb Res; 2022 May; 213 Suppl 1():S66-S71. PubMed ID: 36210563
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer.
    Ueyama H; Miyashita H; Takagi H; Cruz C; Burger A; Briasoulis A; Kuno T
    J Thromb Thrombolysis; 2021 Jan; 51(1):102-111. PubMed ID: 32458316
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anticoagulation Practice in Patients with Cancer-Associated Thrombosis: Insights from GeCAT, a German Prospective Registry Study.
    Klamroth R; Sinn M; Pollich C; Bischoff S; Lohneis A; Orlovic AM; Wisłocka L; Habbel P; de Wit M; Späth-Schwalbe E; Scholz CW; Riess H
    Oncol Res Treat; 2022; 45(4):178-185. PubMed ID: 34963120
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct oral anticoagulant (DOAC) versus low-molecular-weight heparin (LMWH) for the treatment of cancer-associated thrombosis (which agent for which patient).
    Pernod G; Joly M; Sonnet B
    J Med Vasc; 2020 Nov; 45(6S):6S17-6S23. PubMed ID: 33276939
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of direct oral anticoagulants versus low molecular weight heparins for venous thromboembolism treatment in patients with gastrointestinal malignancies.
    Guan T; Laguna A; Soares A; Legasto CS; Block S; Saunders IM; Alvarez K; Pon T; Patel N; Mahajan A; Lee A
    J Thromb Thrombolysis; 2023 Oct; 56(3):439-446. PubMed ID: 37421494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial.
    Lee AYY; Kamphuisen PW; Meyer G; Bauersachs R; Janas MS; Jarner MF; Khorana AA;
    JAMA; 2015 Aug; 314(7):677-686. PubMed ID: 26284719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of Cancer-Associated Venous Thromboembolism with Low-Molecular-Weight Heparin or Direct Oral Anticoagulants: Patient Selection, Controversies, and Caveats.
    O'Connell C; Escalante CP; Goldhaber SZ; McBane R; Connors JM; Raskob GE
    Oncologist; 2021 Jan; 26(1):e8-e16. PubMed ID: 33275319
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer.
    Akl EA; Kahale L; Barba M; Neumann I; Labedi N; Terrenato I; Sperati F; Muti P; Schünemann H
    Cochrane Database Syst Rev; 2014 Jul; (7):CD006650. PubMed ID: 25004410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.